Lonza Group AG (LONN.SW)
Swiss - Swiss Delayed price. Currency in CHF
Add to watchlist
At close: 05:30PM CEST
| Previous close | 488.60 |
| Open | 488.60 |
| Bid | 486.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 480.50 - 489.10 |
| 52-week range | 308.60 - 599.40 |
| Volume | |
| Avg. volume | 212,667 |
| Market cap | 35.078B |
| Beta (5Y monthly) | 0.64 |
| PE ratio (TTM) | 54.65 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 4.00 (0.82%) |
| Ex-dividend date | 13 May 2024 |
| 1y target est | N/A |
- PR Newswire
NeuroSense Announces First Quarter 2024 Business Update
NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing novel treatments for severe neurodegenerative diseases, today provides a business update.
- Business Wire
Vertex and Lonza to Build Dedicated Manufacturing Facility for Type 1 Diabetes (T1D) Cell Therapies
BOSTON & BASEL, Switzerland, June 26, 2023--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Lonza (SIX: LONN) today announced a strategic collaboration to support the manufacture of Vertex’s portfolio of investigational stem cell-derived, fully differentiated insulin-producing islet cell therapies for people with T1D, currently focusing on the VX-880 and VX-264 programs that are currently in clinical trials.
© 2024 Yahoo. All rights reserved.